Savara (SVRA) Rating Lowered to Hold at BidaskClub
Savara (NASDAQ:SVRA) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a report released on Wednesday.
A number of other brokerages also recently commented on SVRA. Canaccord Genuity reiterated a “buy” rating on shares of Savara in a report on Thursday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Savara in a report on Friday, August 3rd. Zacks Investment Research upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 23rd. ValuEngine upgraded shares of Savara from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Finally, Evercore ISI initiated coverage on shares of Savara in a report on Friday, June 8th. They issued an “outperform” rating and a $40.00 target price for the company. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. Savara presently has a consensus rating of “Hold” and an average price target of $22.94.
Shares of Savara stock opened at $10.61 on Wednesday. The stock has a market capitalization of $343.52 million, a price-to-earnings ratio of -6.03 and a beta of -0.24. The company has a quick ratio of 10.30, a current ratio of 10.30 and a debt-to-equity ratio of 0.16. Savara has a one year low of $5.07 and a one year high of $17.19.
In other news, CFO David L. Lowrance sold 5,275 shares of the business’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $12.08, for a total transaction of $63,722.00. Following the sale, the chief financial officer now owns 23,080 shares in the company, valued at $278,806.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert N. Neville sold 17,973 shares of the business’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $12.09, for a total value of $217,293.57. Following the sale, the chief executive officer now owns 402,648 shares in the company, valued at approximately $4,868,014.32. The disclosure for this sale can be found here. Insiders have sold 47,055 shares of company stock worth $569,209 in the last 90 days. Insiders own 6.10% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. SCP Investment LP purchased a new stake in shares of Savara during the second quarter worth about $679,000. MetLife Investment Advisors LLC purchased a new stake in shares of Savara during the second quarter worth about $148,000. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Savara during the second quarter worth about $104,000. Raymond James & Associates purchased a new stake in shares of Savara during the second quarter worth about $469,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Savara by 424.5% during the second quarter. Dimensional Fund Advisors LP now owns 64,828 shares of the company’s stock worth $734,000 after acquiring an additional 52,469 shares during the last quarter. Institutional investors and hedge funds own 42.40% of the company’s stock.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.